Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

Jefferson M. Jones, MD 1 ; Katherine E. Fleming-Dutra, MD 1 ; Mila M. Prill, MSPH 1 ; Lauren E. Roper, MPH 1 ; Oliver Brooks, MD 2 ; Pablo J. Sánchez, MD 3 ; Camille N. Kotton, MD 4 ; Barbara E. Mahon, MD 1 ; Sarah Meyer, MD 5 ; Sarah S. Long, MD 6 ; Meredith L. McMorrow, MD 1 ( View author affiliations )

View suggested citation Summary

What is already known about this topic? In July 2023, the Food and Drug Administration approved nirsevimab, a long-acting monoclonal antibody, for prevention of respiratory syncytial […]

Click here to visit source. www.cdc.gov